Not available
Quote | Verastem Inc. (NASDAQ:VSTM)
Last: | $9.28 |
---|---|
Change Percent: | -0.32% |
Open: | $9.13 |
Close: | $9.31 |
High: | $9.38 |
Low: | $9.02 |
Volume: | 57,349 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Verastem Inc. (NASDAQ:VSTM)
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...
Message Board Posts | Verastem Inc. (NASDAQ:VSTM)
Subject | By | Source | When |
---|---|---|---|
Happy I hit and run. I would consider | Harbor6460 | investorshub | 06/09/2023 4:06:50 PM |
$VSTM The gaining | Tartiaboy | investorshub | 06/08/2023 9:42:19 PM |
$VSTM news all the way baby | Tartiaboy | investorshub | 06/04/2023 12:16:39 PM |
They definite are diluting. They need money. | Harbor6460 | investorshub | 05/29/2023 2:44:48 PM |
highest volume in history -insert dd- | The Night Stalker | investorshub | 05/29/2023 5:53:28 AM |
News, Short Squeeze, Breakout and More Instantly...
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...